Woman Presents With a Brain Mass

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.

Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.